Résumé
<p><b>OBJECTIVE</b>To investigate the value of technetium-99m methoxyisobutylisonitrile ((99)Tc(m)-MIBI) imaging in predicting the efficacy of neoadjuvant chemotherapy (NCT) and prognosis in patients with operable breast cancer.</p><p><b>METHODS</b>Sixty five patients with breast cancer underwent (99)Tc(m)-MIBI scintimammography before NCT, and static planar images were taken at 10 min and 180 min after scintimammography. The clearance rate was calculated in each patient, correlation between the clearance rate and efficacy of NCT, and the disease free survival rate were analyzed.</p><p><b>RESULTS</b>The mean clearance rate of 65 patients was (17.4 ± 6.8)%. The efficacy of NCT was 86.2% (CR 4 cases, PR 52 cases, SD 8 cases, and PD 1 case), and the mean clearance rate of patients with good response or poor response of chemotherapy were (15.5 ± 5.0)% and (29.2 ± 3.2)%, respectively. There was a significant difference between the two groups. The average disease free survival rate in the group with low clearance rate was (75.8%, P = 0.046), significantly higher than that in the group with high clearance rate (53.1%).</p><p><b>CONCLUSION</b>Scintimammography of (99)Tc(m)-MIBI may be used to evaluate the efficacy and prognosis of NCT for patients with operable breast cancer.</p>
Sujets)
Adulte , Sujet âgé , Femelle , Humains , Adulte d'âge moyen , Protocoles de polychimiothérapie antinéoplasique , Utilisations thérapeutiques , Tumeurs du sein , Imagerie diagnostique , Traitement médicamenteux , Carcinome canalaire du sein , Imagerie diagnostique , Traitement médicamenteux , Carcinome lobulaire , Imagerie diagnostique , Traitement médicamenteux , Traitement médicamenteux adjuvant , Cyclophosphamide , Utilisations thérapeutiques , Survie sans rechute , Épirubicine , Utilisations thérapeutiques , Étoposide , Utilisations thérapeutiques , Fluorouracil , Utilisations thérapeutiques , Études de suivi , Traitement néoadjuvant , Stadification tumorale , Valeur prédictive des tests , Scintigraphie , Radiopharmaceutiques , Induction de rémission , Taxoïdes , Utilisations thérapeutiques , Technétium (99mTc) sestamibiRésumé
<p><b>OBJECTIVE</b>To evaluate the relationship between the clearance rate of technetium-99m methoxyisobutylisonitrile ((99m)Tc-MIBI) in scintimammography and multidrug-resistant proteins expression in breast cancer tissues.</p><p><b>METHODS</b>Seventy-six patients with breast cancer underwent (99m)Tc-MIBI scintimammography before treatment, and static planar images were taken at 10 min and 180 min after scintimammography. The clearance rate of (99m)Tc-MIBI was calculated in each patient. Immunohistochemical analysis was performed on pathological specimens of the 76 breast tumors to determine the expression of P-glycoprotein (P-gp), glutathione S-transferase Pi (GST-pi) and topoisomerase II (Topo II).</p><p><b>RESULTS</b>The clearance rate was significantly higher in 36 patients with positive P-gp expression when compared with that in 40 patients with negative P-gp expression. There was no significant relationship between GST-pi, Topo II and the clearance rate of (99m)Tc-MIBI.</p><p><b>CONCLUSION</b>The clearance rate of (99m)Tc-MIBI in breast imaging may be used to evaluate the P-gp level in breast cancers.</p>